Celyad Oncology SA
CLYYF
$0.25
-$0.10-28.57%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.50K | 111.10K | 201.50K | 201.10K | 201.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.50K | 111.10K | 201.50K | 201.10K | 201.30K |
| Cost of Revenue | 8.70K | 10.30K | 11.90K | 12.20K | 12.90K |
| Gross Profit | 14.80K | 100.80K | 189.60K | 188.90K | 188.40K |
| SG&A Expenses | 4.29M | 3.84M | 3.42M | 3.40M | 3.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -6.71M | -3.52M | -328.00K | -372.60K | -422.00K |
| Total Operating Expenses | 1.42M | 4.29M | 7.21M | 6.80M | 6.55M |
| Operating Income | -1.40M | -4.18M | -7.01M | -6.60M | -6.35M |
| Income Before Tax | 1.24M | -2.87M | -7.03M | -6.58M | -6.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.24 | -2.87 | -7.03 | -6.58 | -6.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.24M | -2.87M | -7.03M | -6.58M | -6.30M |
| EBIT | -1.40M | -4.18M | -7.01M | -6.60M | -6.35M |
| EBITDA | -1.13M | -3.87M | -6.66M | -6.24M | -5.98M |
| EPS Basic | 0.02 | -0.07 | -0.17 | -0.16 | -0.15 |
| Normalized Basic EPS | -0.02 | -0.06 | -0.11 | -0.10 | -0.09 |
| EPS Diluted | 0.01 | -0.08 | -0.17 | -0.16 | -0.15 |
| Normalized Diluted EPS | -0.03 | -0.07 | -0.11 | -0.10 | -0.09 |
| Average Basic Shares Outstanding | 171.12M | 168.42M | 165.71M | 167.77M | 167.77M |
| Average Diluted Shares Outstanding | 185.07M | 175.39M | 165.71M | 167.77M | 167.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |